Breast Cancer Plasticity after Chemotherapy Highlights the Need for Re-Evaluation of Subtyping in Residual Cancer and Metastatic Tissues
Authors:
- Irena Barbara Padzińska-PruszyńskaIPIrena Barbara Padzińska-Pruszyńska
- Muhammad Waqas AkbarMAMuhammad Waqas Akbar
- Murat IsbilenMIMurat Isbilen
- Emilia GórkaEGEmilia Górka
- Baris KucukkaradumanBKBaris Kucukkaraduman
- Seçil Demirkol CanlıSCSeçil Demirkol Canlı
- Ege DedeoğluEDEge Dedeoğlu
- Shila AzizolliSAShila Azizolli
- Isli CelaICIsli Cela
- Abbas Guven AkcayAAAbbas Guven Akcay
- Hasim HakanogluHHHasim Hakanoglu
- Lubomir BodnarLBLubomir Bodnar
Open Access
- 31 May 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6054
Abstract
This research paper presents a novel approach to identifying biomarkers that can be used to prognosticate patients with triple-negative breast cancer (TNBC) eligible for neoadjuvant therapy. The study utilized survival and RNA sequencing data from a cohort of TNBC patients and identified 276 genes whose expression was related to survival in such patients. The gene expression data were then used to classify patients into two major groups based on the presence or absence of Wingless/Integrated-pathway (Wnt-pathway) and mesenchymal (Mes) markers (Wnt/Mes). Patients with a low expression of Wnt/Mes-related genes had a favorable outcome, with no deaths observed during follow-up, while patients with a high expression of Wnt/Mes genes had a higher mortality rate of 50% within 19 months. The identified gene list could be validated and potentially used to shape treatment options for TNBC patients eligible for neoadjuvant therapy providing valuable insights into the development of more effective treatments for TNBC. Our data also showed significant variation in gene expression profiles before and after chemotherapy, with most tumors switching to a more mesenchymal/stem cell-like profile. To verify this observation, we performed an in silico analysis to classify breast cancer tumors in Prediction Analysis of Microarray 50 (PAM50) molecular classes before treatment and after treatment using gene expression data. Our findings demonstrate that following drug intervention and metastasis, certain tumors undergo a transition to alternative subtypes, resulting in diminished therapeutic efficacy. This underscores the necessity for reevaluation of patients who have experienced relapse or metastasis post-chemotherapy, with a focus on molecular subtyping. Tailoring treatment strategies based on these refined subtypes is imperative to optimize therapeutic outcomes for affected individuals.Keywords
Funding Information
- Narodowe Centrum Badań i Rozwoju (POLTUR2/PCTNBC/30/2016)
This publication has 24 references indexed in Scilit:
- Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer MetastasisCellular and Molecular Bioengineering, 2021
- Breast cancerNature Reviews Disease Primers, 2019
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)Annals of Oncology, 2018
- Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast CancerCancer Research, 2017
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresProceedings of the National Academy of Sciences, 2009
- Breast cancer metastases are molecularly distinct from their primary tumorsOncogene, 2007
- Assessment of Optimal Selected Prognostic FactorsBiometrical Journal, 2004
- Java Treeview—extensible visualization of microarray dataBioinformatics, 2004
- Open source clustering softwareBioinformatics, 2004
- On the exact distribution of maximally selected rank statisticsComputational Statistics & Data Analysis, 2003